|
1
|
Rubin LJ, Badesch DB, Barst RJ, Galie N,
Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al:
Bosentan therapy for pulmonary arterial hypertension. N Engl J Med.
346:896–903. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Humbert M, Deng Z, Simonneau G, Barst RJ,
Sitbon O, Wolf M, Cuervo N, Moore KJ, Hodge SE, Knowles JA and
Morse JH: BMPR2 germline mutations in pulmonary hypertension
associated with fenfluramine derivatives. Eur Respir J. 20:518–523.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Humbert M, Sitbon O and Simonneau G:
Treatment of pulmonary arterial hypertension. N Engl J Med.
351:1425–1436. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Walker J, Undem C, Yun X, Lade J, Jiang H
and Shimoda LA: Role of Rho kinase and Na+/H+
exchange in hypoxia-induced pulmonary arterial smooth muscle cell
proliferation and migration. Physiol Rep. 4:e127022016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hou X, Chen J, Luo Y, Liu F, Xu G and Gao
Y: Silencing of STIM1 attenuates hypoxia-induced PASMCs
proliferation via inhibition of the SOC/Ca2+/NFAT
pathway. Respir Res. 14:22013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Heldin CH and Westermark B: Mechanism of
action and in vivo role of platelet-derived growth factor. Physiol
Rev. 79:1283–1316. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cimminiello C, Arpaia G, Aloisio M, Uberti
T, Rossi F, Pozzi F and Bonfardeci G: Platelet-derived growth
factor (PDGF) in patients with different degrees of chronic
arterial obstructive disease. Angiology. 45:289–293. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Perros F, Montani D, Dorfmüller P,
Durand-Gasselin I, Tcherakian C, Le Pavec J, Mazmanian M, Fadel E,
Mussot S, Mercier O, et al: Platelet-derived growth factor
expression and function in idiopathic pulmonary arterial
hypertension. Am J Respir Crit Care Med. 178:81–88. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Antoniu SA: Targeting PDGF pathway in
pulmonary arterial hypertension. Expert Opin Ther Targets.
16:1055–1063. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Schermuly RT, Dony E, Ghofrani HA,
Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N,
Seeger W and Grimminger F: Reversal of experimental pulmonary
hypertension by PDGF inhibition. J Clin Invest. 115:2811–2821.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Macian F: NFAT proteins: Key regulators of
T-cell development and function. Nat Rev Immunol. 5:472–484. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dorfmüller P, Perros F, Balabanian K and
Humbert M: Inflammation in pulmonary arterial hypertension. Eur
Respir J. 22:358–363. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Voelkel NF, Cool C, Lee SD, Wright L,
Geraci MW and Tuder RM: Primary pulmonary hypertension between
inflammation and cancer. Chest. 114 (Suppl 3):225S–230S. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Vihma H, Pruunsild P and Timmusk T:
Alternative splicing and expression of human and mouse NFAT genes.
Genomics. 92:279–291. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Senavirathna LK, Huang C, Yang X, Munteanu
MC, Sathiaseelan R, Xu D, Henke CA and Liu L: Hypoxia induces
pulmonary fibroblast proliferation through NFAT signaling. Sci Rep.
8:27092018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bonnet S, Rochefort G, Sutendra G, Archer
SL, Haromy A, Webster L, Hashimoto K, Bonnet SN and Michelakis ED:
The nuclear factor of activated T cells in pulmonary arterial
hypertension can be therapeutically targeted. Proc Natl Acad Sci
USA. 104:11418–11423. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Chen R, Yan J, Liu P, Wang Z, Wang C,
Zhong W and Xu L: The role of nuclear factor of activated T cells
in pulmonary arterial hypertension. Cell Cycle. 16:508–514. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
MacLean MMR: The serotonin hypothesis in
pulmonary hypertension revisited: Targets for novel therapies (2017
Grover conference series). Pulm Circ. 8:20458940187591252018.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Maroteaux L, Ayme-Dietrich E,
Aubertin-Kirch G, Banas S, Quentin E, Lawson R and Monassier L: New
therapeutic opportunities for 5-HT2 receptor ligands.
Pharmacol Ther. 170:14–36. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Han J, Tian H, Liu Y and Fan F:
Sarpogrelate attenuates pulmonary arterial hypertension via
calcium/calcineurin axis. Front Biosci (Landmark Ed). 24:607–615.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hassoun PM, Mouthon L, Barberà JA,
Eddahibi S, Flores SC, Grimminger F, Jones PL, Maitland ML,
Michelakis ED, Morrell NW, et al: Inflammation, growth factors, and
pulmonary vascular remodeling. J Am Coll Cardiol. 54 (Suppl
1):S10–S19. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yao C, Yu J, Taylor L, Polgar P, McComb ME
and Costello CE: Protein expression by human pulmonary artery
smooth muscle cells containing a BMPR2 mutation and the action of
ET-1 as determined by proteomic mass spectrometry. Int J Mass
Spectrom. 378:347–359. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nabbi A and Riabowol K: Rapid isolation of
nuclei from cells in vitro. Cold Spring Harb Protoc. 2015:769–772.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Rodriguez LG, Wu X and Guan JL:
Wound-healing assay. Methods Mol Biol. 294:23–29. 2005.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gong L, Zhu L, Wang S and Zhang Z:
Transthyretin regulates the migration and invasion of JEG-3 cells.
Oncol Lett. 13:1242–1246. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vihma H, Luhakooder M, Pruunsild P and
Timmusk T: Regulation of different human NFAT isoforms by neuronal
activity. J Neurochem. 137:394–408. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fukumoto Y, Tawara S and Shimokawa H:
Recent progress in the treatment of pulmonary arterial
hypertension: Expectation for rho-kinase inhibitors. Tohoku J Exp
Med. 211:309–320. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Nie X, Chen Y, Tan J, Dai Y, Mao W, Qin G,
Ye S, Sun J, Yang Z and Chen J: MicroRNA-221-3p promotes pulmonary
artery smooth muscle cells proliferation by targeting AXIN2 during
pulmonary arterial hypertension. Vascul Pharmacol. 116:24–35. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sysol JR, Natarajan V and Machado RF: PDGF
induces SphK1 expression via Egr-1 to promote pulmonary artery
smooth muscle cell proliferation. Am J Physiol Cell Physiol.
310:C983–C992. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pullamsetti SS, Savai R, Seeger W and
Goncharova EA: Translational advances in the field of pulmonary
hypertension. From cancer biology to new pulmonary arterial
hypertension therapeutics. Targeting cell growth and proliferation
signaling hubs. Am J Respir Crit Care Med. 195:425–437. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
He RL, Wu ZJ, Liu XR, Gui LX, Wang RX and
Lin MJ: Calcineurin/NFAT signaling modulates pulmonary artery
smooth muscle cell proliferation, migration and apoptosis in
monocrotaline-induced pulmonary arterial hypertension rats. Cell
Physiol Biochem. 49:172–189. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Potier M, Gonzalez JC, Motiani RK,
Abdullaev IF, Bisaillon JM, Singer HA and Trebak M: Evidence for
STIM1- and Orai1-dependent store-operated calcium influx through
ICRAC in vascular smooth muscle cells: Role in proliferation and
migration. FASEB J. 23:2425–2437. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Earley S and Brayden JE: Transient
receptor potential channels in the vasculature. Physiol Rev.
95:645–690. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Song S, Carr SG, McDermott KM, Rodriguez
M, Babicheva A, Balistrieri A, Ayon RJ, Wang J, Makino A and Yuan
JX: STIM2 (stromal interaction molecule 2)-mediated increase in
resting cytosolic free Ca2+ concentration stimulates
PASMC proliferation in pulmonary arterial hypertension.
Hypertension. 71:518–529. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kao SC, Wu H, Xie J, Chang CP, Ranish JA,
Graef IA and Crabtree GR: Calcineurin/NFAT signaling is required
for neuregulin-regulated Schwann cell differentiation. Science.
323:651–654. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Razmara M, Heldin CH and Lennartsson J:
Platelet-derived growth factor-induced Akt phosphorylation requires
mTOR/Rictor and phospholipase C-γ1, whereas S6 phosphorylation
depends on mTOR/Raptor and phospholipase D. Cell Commun Signal.
11:32013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Ogawa A, Firth AL, Smith KA, Maliakal MV
and Yuan JX: PDGF enhances store-operated Ca2+ entry by
upregulating STIM1/Orai1 via activation of Akt/mTOR in human
pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol.
302:C405–C411. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
O'Callaghan DS, Savale L, Montani D, Jaïs
X, Sitbon O, Simonneau G and Humbert M: Treatment of pulmonary
arterial hypertension with targeted therapies. Nat Rev Cardiol.
8:526–538. 2011. View Article : Google Scholar : PubMed/NCBI
|
